<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919761</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14294063</org_study_id>
    <nct_id>NCT02919761</nct_id>
  </id_info>
  <brief_title>A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      2 part multicenter study to examine the effect of Acthar in adult subjects with rheumatoid
      arthritis (RA) with persistently active disease. Part 1 is an Open Label Period in which all
      eligible subjects receive Acthar for 12 weeks. After 12 weeks of treatment with Acthar,
      subjects will be evaluated for treatment response using the DAS28-ESR. Subjects who have
      achieved low disease activity will enter a double-blind randomized maintenance period (Part
      2) and be randomized in a 1:1 ratio to receive either Acthar or matching placebo for an
      additional 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with Disease Activity Score with 28 joint count and Erythrocyte Sedimentation Rate (DAS28-ESR)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Proportion of subjects with DAS28-ESR &lt;3.2 at Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who maintained DAS28-ESR</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Proportion of subjects with Low Disease Activity as defined by DAS28-ESR &lt;3.2 at Week 24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acthar 1 mL (80 U) 2x/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acthar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acthar 1 mL (80 U) 2x/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_label>Acthar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must meet criteria for rheumatoid arthritis as defined by 2010 American
             College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
             classification at screening.

          2. Subjects must have persistently active rheumatoid arthritis defined as DAS 28-ESR &gt;
             3.2 at screening.

          3. Subjects must have been on a corticosteroid 12 weeks prior to screening, with a
             stable dose of 5-10 mg prednisone (or prednisone equivalent) for 4 weeks prior to
             screening.

          4. Subjects must have been on either a non-biologic or biologic treatment in the 12
             weeks prior to screening.

        Exclusion Criteria:

          1. Subjects cannot have used intra-articular steroids within 14 days of the screening
             visit.

          2. Subjects cannot have any known contraindication to Acthar.

          3. Subjects cannot have Type 1 or Type 2 diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leonor Nazareno</last_name>
    <phone>908-238-6638</phone>
    <email>leonor.nazareno@mallinckrodt.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>September 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>persistant disease activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
